[Severe hemoptysis in the onco-hematology patient]

Rev Mal Respir. 2024 Apr;41(4):303-316. doi: 10.1016/j.rmr.2023.11.004. Epub 2023 Dec 27.
[Article in French]

Abstract

In France, even though it occurs only exceptionally in cases of hemopathy, severe hemoptysis in cancer is the leading cause of hemoptysis. Without adequate treatment, in-hospital mortality exceeds 60%, even reaching 100% at 6 months. The management of severe hemoptysis should be discussed with the oncologist. Aside from situations of threatening hemoptysis, in which bronchoscopy should be performed immediately, CT angiography is an essential means of localizing the bleeding and determining the causes and the vascular mechanisms involved. In more than 90% of cases, hemoptysis is linked to systemic bronchial or non-bronchial hypervascularization, whereas in fewer than 5%, it is associated with pulmonary arterial origin or, exceptionally, with damage to the alveolar-capillary barrier. The most severely ill patients must be treated in intensive care in centers equipped with interventional radiology, thoracic surgery and, ideally, with interventional bronchoscopy. Interventional radiology is the first-line symptomatic treatment. In over 80% of cases, bronchial arteriography with embolization allows immediate control. Emergency surgery should be avoided, as it is associated with significant mortality. Appropriate and adequate care reduces hospital mortality to 30%, enabling patients to benefit from the most recent, survival-prolonging treatments.

Keywords: Angio-TDM thoracique; Artériographie bronchique; Bronchial arteriography; Cancer pulmonaire; Chest CT scan; Hémoptysie grave; Lung neoplasms; Severe hemoptysis.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Bronchi
  • Bronchoscopy / adverse effects
  • Embolization, Therapeutic* / adverse effects
  • Hematology*
  • Hemoptysis / diagnosis
  • Hemoptysis / etiology
  • Hemoptysis / therapy
  • Humans